Renal cell carcinoma

ALLO-316 is an anti-CD70 AlloCAR T™ candidate for renal cell carcinoma (RCC) as well as several hematological malignancies

CD70 expression1

  • RCC (80%-100%)​
  • Acute myeloid leukemia (96%)​
  • Diffuse large B cell lymphoma (71%), multiple myeloma (63%), chronic lymphocytic leukemia (50%)​
  • Glioblastoma mutiforme (35%)​
  • CD70 is also expressed on activated T cells

CD70 in RCC

  • High prevalence with limited off-tumor expression​
  • Good expression in metastatic disease

ALLO-316 is associated with minimal or no fratricide